Change From Baseline (CFB) in EORTC QLQ 20-item Multiple Myeloma Module (MY20) Score
Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) · Source last updated 2026-07-01
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
Measure
MEAN
Unit
Scores on Scale
Interval / dispersion
Standard Deviation
Time frame
Baseline (Day 1), every three weeks(Q3W) starting from week 4 until week 238, End of Treatment (~242 weeks) and Follow up (~263 weeks)
What was measured
The EORTC QLQ-MY20 is a supplement to the QLQ-C30 instrument used in participants with multiple myeloma. The module comprised of 20 questions that addressed four myeloma-specific HRQoL domains: disease symptoms (DS), side effects of treatment (SET), future perspective (FP) and body image (BI). Responses are 1 to 4. Scores were averaged and scales were transformed to 0 to 100 scale. A high score for disease symptoms and side effects of treatment represented a high level of symptomatology or problems, whereas a high score for future perspective and body image represented better outcomes. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits.
Analysis population: ITT Population. Only those participants with data available in specified timepoints have been presented. Rows and Arms/Groups with 0 participants analyzed represent time points at which no participant data was available from within the respective Arms/Groups.
Groups in this outcome
Belantamab Mafodotin
Participants with relapsed/refractory multiple myeloma (RRMM) received 30 minutes intravenous infusion of 2.5 milligram/kilogram (mg/kg) belantamab mafodotin on day 1 of each 21-day cycle
Pomalidomide Plus Dexamethasone
Participants with RRMM received 4 mg pomalidomide capsule daily on Days 1 to 21 of each 28-day cycle, along with 40 mg or at lower 20 mg (for participants \>75 years of age) dose of dexamethasone tablet once weekly (Days 1, 8, 15 and 22)
Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
218
Pomalidomide Plus Dexamethasone
107
Reported measurements
BI, CFB to Week 4
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
33
Pomalidomide Plus Dexamethasone
14
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
7.07
21.663
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
7.14
19.298
Not reported
Not reported
Not reported
BI, CFB to Week 7
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
30
Pomalidomide Plus Dexamethasone
16
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
-4.44
27.310
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
2.08
19.124
Not reported
Not reported
Not reported
BI, CFB to Week 10
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
27
Pomalidomide Plus Dexamethasone
12
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
-1.23
21.645
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
5.56
19.245
Not reported
Not reported
Not reported
BI, CFB to Week 13
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
25
Pomalidomide Plus Dexamethasone
13
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
1.33
20.367
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
5.13
22.958
Not reported
Not reported
Not reported
BI, CFB to Week 16
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
24
Pomalidomide Plus Dexamethasone
15
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
-4.17
26.580
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
-4.44
24.774
Not reported
Not reported
Not reported
BI, CFB to Week 19
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
22
Pomalidomide Plus Dexamethasone
12
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
-3.03
20.339
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
11.11
21.711
Not reported
Not reported
Not reported
BI, CFB to Week 22
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
23
Pomalidomide Plus Dexamethasone
12
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
5.80
21.678
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
0.00
14.213
Not reported
Not reported
Not reported
BI, CFB to Week 25
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
24
Pomalidomide Plus Dexamethasone
6
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
-1.39
23.008
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
0.00
21.082
Not reported
Not reported
Not reported
BI, CFB to Week 28
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
21
Pomalidomide Plus Dexamethasone
8
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
4.76
21.822
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
0.00
25.198
Not reported
Not reported
Not reported
BI, CFB to Week 31
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
21
Pomalidomide Plus Dexamethasone
8
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
4.76
24.234
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
8.33
23.570
Not reported
Not reported
Not reported
BI, CFB to Week 34
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
19
Pomalidomide Plus Dexamethasone
7
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
5.26
25.491
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
4.76
23.002
Not reported
Not reported
Not reported
BI, CFB to Week 37
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
18
Pomalidomide Plus Dexamethasone
8
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
0.00
28.006
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
-4.17
21.362
Not reported
Not reported
Not reported
BI, CFB to Week 40
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
18
Pomalidomide Plus Dexamethasone
8
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
3.70
22.547
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
0.00
25.198
Not reported
Not reported
Not reported
BI, CFB to Week 43
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
18
Pomalidomide Plus Dexamethasone
7
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
1.85
21.305
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
0.00
27.217
Not reported
Not reported
Not reported
BI, CFB to Week 46
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
16
Pomalidomide Plus Dexamethasone
5
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
4.17
16.667
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
6.67
27.889
Not reported
Not reported
Not reported
BI, CFB to Week 49
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
17
Pomalidomide Plus Dexamethasone
6
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
5.88
24.254
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
-5.56
32.773
Not reported
Not reported
Not reported
BI, CFB to Week 52
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
14
Pomalidomide Plus Dexamethasone
7
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
2.38
20.524
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
4.76
23.002
Not reported
Not reported
Not reported
BI, CFB to Week 55
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
13
Pomalidomide Plus Dexamethasone
7
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
-5.13
12.518
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
-4.76
35.635
Not reported
Not reported
Not reported
BI, CFB to Week 58
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
14
Pomalidomide Plus Dexamethasone
7
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
0.00
22.646
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
4.76
23.002
Not reported
Not reported
Not reported
BI, CFB to Week 61
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
14
Pomalidomide Plus Dexamethasone
7
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
-2.38
15.821
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
0.00
27.217
Not reported
Not reported
Not reported
BI, CFB to Week 64
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
218
Pomalidomide Plus Dexamethasone
5
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
5.13
22.958
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
6.67
27.889
Not reported
Not reported
Not reported
BI, CFB to Week 67
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
14
Pomalidomide Plus Dexamethasone
5
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
-2.38
20.524
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
0.00
33.333
Not reported
Not reported
Not reported
BI, CFB to Week 70
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
13
Pomalidomide Plus Dexamethasone
5
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
0.00
19.245
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
0.00
33.333
Not reported
Not reported
Not reported
BI, CFB to Week 73
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
10
Pomalidomide Plus Dexamethasone
5
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
-6.67
21.082
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
6.67
27.889
Not reported
Not reported
Not reported
BI, CFB to Week 76
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
12
Pomalidomide Plus Dexamethasone
5
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
-8.33
25.126
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
0.00
33.333
Not reported
Not reported
Not reported
BI, CFB to Week 79
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
11
Pomalidomide Plus Dexamethasone
5
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
3.03
27.707
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
0.00
33.333
Not reported
Not reported
Not reported
BI, CFB to Week 82
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
11
Pomalidomide Plus Dexamethasone
5
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
9.09
21.556
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
6.67
27.889
Not reported
Not reported
Not reported
BI, CFB to Week 85
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
8
Pomalidomide Plus Dexamethasone
3
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
4.17
21.362
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
0.00
33.333
Not reported
Not reported
Not reported
BI, CFB to Week 88
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
11
Pomalidomide Plus Dexamethasone
3
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
-15.15
22.918
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
0.00
33.333
Not reported
Not reported
Not reported
BI, CFB to Week 91
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
8
Pomalidomide Plus Dexamethasone
3
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
-8.33
15.430
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
0.00
33.333
Not reported
Not reported
Not reported
BI, CFB to Week 94
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
10
Pomalidomide Plus Dexamethasone
3
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
-3.33
18.922
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
0.00
33.333
Not reported
Not reported
Not reported
BI, CFB to Week 97
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
8
Pomalidomide Plus Dexamethasone
3
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
4.17
11.785
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
0.00
33.333
Not reported
Not reported
Not reported
BI, CFB to Week 100
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
7
Pomalidomide Plus Dexamethasone
3
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
9.52
25.198
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
-11.11
19.245
Not reported
Not reported
Not reported
BI, CFB to Week 103
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
8
Pomalidomide Plus Dexamethasone
3
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
0.00
25.198
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
-22.22
19.245
Not reported
Not reported
Not reported
BI, CFB to Week 106
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
6
Pomalidomide Plus Dexamethasone
1
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
5.56
25.092
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
-33.33
NA
Not reported
Not reported
Standard Deviation is not evaluable for a single participant.
BI, CFB to Week 109
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
8
Pomalidomide Plus Dexamethasone
3
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
0.00
25.198
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
-11.11
38.490
Not reported
Not reported
Not reported
BI, CFB to Week 112
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
6
Pomalidomide Plus Dexamethasone
2
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
11.11
27.217
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
-33.33
0.000
Not reported
Not reported
Not reported
BI, CFB to Week 115
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
7
Pomalidomide Plus Dexamethasone
3
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
4.76
23.002
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
-22.22
19.245
Not reported
Not reported
Not reported
BI, CFB to Week 118
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
7
Pomalidomide Plus Dexamethasone
3
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
-4.76
23.002
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
-22.22
19.245
Not reported
Not reported
Not reported
BI, CFB to Week 121
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
7
Pomalidomide Plus Dexamethasone
3
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
0.00
19.245
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
-33.33
33.333
Not reported
Not reported
Not reported
BI, CFB to Week 124
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
5
Pomalidomide Plus Dexamethasone
2
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
-13.33
18.257
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
-33.33
0.000
Not reported
Not reported
Not reported
BI, CFB to Week 127
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
6
Pomalidomide Plus Dexamethasone
2
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
0.00
21.082
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
0.00
0.00
Not reported
Not reported
Not reported
BI, CFB to Week 130
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
6
Pomalidomide Plus Dexamethasone
1
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
5.56
25.092
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
0.00
NA
Not reported
Not reported
Standard Deviation is not evaluable for a single participant.
BI, CFB to Week 133
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
5
Pomalidomide Plus Dexamethasone
2
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
6.67
14.907
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
-16.67
23.570
Not reported
Not reported
Not reported
BI, CFB to Week 136
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
3
Pomalidomide Plus Dexamethasone
1
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
0.00
0.00
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
0.00
NA
Not reported
Not reported
Standard Deviation is not evaluable for a single participant.
BI, CFB to Week 139
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
4
Pomalidomide Plus Dexamethasone
2
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
-8.33
16.667
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
-33.33
47.140
Not reported
Not reported
Not reported
BI, CFB to Week 142
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
4
Pomalidomide Plus Dexamethasone
0
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
8.33
16.667
Not reported
Not reported
Not reported
BI, CFB to Week 145
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
3
Pomalidomide Plus Dexamethasone
1
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
11.11
19.245
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
0.00
NA
Not reported
Not reported
Standard Deviation is not evaluable for a single participant.
BI, CFB to Week 148
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
3
Pomalidomide Plus Dexamethasone
1
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
0.00
33.333
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
0.00
NA
Not reported
Not reported
Standard Deviation is not evaluable for a single participant.
BI, CFB to Week 151
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
3
Pomalidomide Plus Dexamethasone
1
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
22.22
19.245
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
0.00
NA
Not reported
Not reported
Standard Deviation is not evaluable for a single participant.
BI, CFB to Week 154
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
2
Pomalidomide Plus Dexamethasone
1
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
-16.67
23.570
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
0.00
NA
Not reported
Not reported
Standard Deviation is not evaluable for a single participant.
BI, CFB to Week 157
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
4
Pomalidomide Plus Dexamethasone
0
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
0.00
27.217
Not reported
Not reported
Not reported
BI, CFB to Week 160
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
3
Pomalidomide Plus Dexamethasone
0
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
11.11
19.245
Not reported
Not reported
Not reported
BI, CFB to Week 163
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
2
Pomalidomide Plus Dexamethasone
0
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
16.67
23.570
Not reported
Not reported
Not reported
BI, CFB to Week 166
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
2
Pomalidomide Plus Dexamethasone
0
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
16.67
23.570
Not reported
Not reported
Not reported
BI, CFB to Week 169
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
2
Pomalidomide Plus Dexamethasone
0
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
16.67
23.570
Not reported
Not reported
Not reported
BI, CFB to Week 172
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
1
Pomalidomide Plus Dexamethasone
0
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
33.33
NA
Not reported
Not reported
Standard Deviation is not evaluable for a single participant.
BI, CFB to Week 175
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
1
Pomalidomide Plus Dexamethasone
0
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
33.33
NA
Not reported
Not reported
Standard Deviation is not evaluable for a single participant.
BI, CFB to Week 178
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
1
Pomalidomide Plus Dexamethasone
0
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
33.33
NA
Not reported
Not reported
Standard Deviation is not evaluable for a single participant.
BI, CFB to Week 181
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
1
Pomalidomide Plus Dexamethasone
0
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
33.33
NA
Not reported
Not reported
Standard Deviation is not evaluable for a single participant.
BI, CFB to EOT (~242 weeks)
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
23
Pomalidomide Plus Dexamethasone
13
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
-10.14
29.189
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
-5.13
18.490
Not reported
Not reported
Not reported
BI, CFB to LFU (~263 weeks)
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
15
Pomalidomide Plus Dexamethasone
3
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
-11.11
27.217
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
-11.11
19.245
Not reported
Not reported
Not reported
DS, CFB to Week 4
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
173
Pomalidomide Plus Dexamethasone
80
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
-2.54
15.169
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
-3.16
14.272
Not reported
Not reported
Not reported
DS, CFB to Week 7
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
144
Pomalidomide Plus Dexamethasone
77
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
-2.38
16.226
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
-5.76
16.668
Not reported
Not reported
Not reported
DS, CFB to Week 10
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
128
Pomalidomide Plus Dexamethasone
65
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
-3.71
16.488
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
-4.82
17.445
Not reported
Not reported
Not reported
DS, CFB to Week 13
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
110
Pomalidomide Plus Dexamethasone
58
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
-4.67
18.590
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
-7.05
16.100
Not reported
Not reported
Not reported
DS, CFB to Week 16
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
104
Pomalidomide Plus Dexamethasone
53
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
-5.51
17.544
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
-5.85
18.479
Not reported
Not reported
Not reported
DS, CFB to Week 19
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
96
Pomalidomide Plus Dexamethasone
50
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
-5.05
20.806
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
-5.67
19.650
Not reported
Not reported
Not reported
DS, CFB to Week 22
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
95
Pomalidomide Plus Dexamethasone
42
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
-4.08
19.689
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
-6.46
18.330
Not reported
Not reported
Not reported
DS, CFB to Week 25
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
88
Pomalidomide Plus Dexamethasone
34
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
-6.92
16.442
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
-6.54
16.382
Not reported
Not reported
Not reported
DS, CFB to Week 28
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
82
Pomalidomide Plus Dexamethasone
34
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
-4.01
19.672
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
-7.68
19.487
Not reported
Not reported
Not reported
DS, CFB to Week 31
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
74
Pomalidomide Plus Dexamethasone
33
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
-4.28
18.536
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
-7.24
18.865
Not reported
Not reported
Not reported
DS, CFB to Week 34
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
70
Pomalidomide Plus Dexamethasone
24
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
-4.21
16.739
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
-6.25
11.735
Not reported
Not reported
Not reported
DS, CFB to Week 37
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
66
Pomalidomide Plus Dexamethasone
24
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
-7.12
19.892
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
-3.47
14.075
Not reported
Not reported
Not reported
DS, CFB to Week 40
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
65
Pomalidomide Plus Dexamethasone
23
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
-8.32
18.363
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
-3.04
12.989
Not reported
Not reported
Not reported
DS, CFB to Week 43
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
67
Pomalidomide Plus Dexamethasone
18
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
-7.50
19.751
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
-3.09
14.664
Not reported
Not reported
Not reported
DS, CFB to Week 46
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
63
Pomalidomide Plus Dexamethasone
13
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
-9.01
17.512
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
-3.85
16.879
Not reported
Not reported
Not reported
DS, CFB to Week 49
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
62
Pomalidomide Plus Dexamethasone
16
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
-6.74
17.359
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
-3.13
20.883
Not reported
Not reported
Not reported
DS, CFB to Week 52
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
60
Pomalidomide Plus Dexamethasone
17
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
-8.83
17.943
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
-5.88
14.760
Not reported
Not reported
Not reported
DS, CFB to Week 55
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
59
Pomalidomide Plus Dexamethasone
16
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
-7.01
19.811
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
-1.39
14.558
Not reported
Not reported
Not reported
DS, CFB to Week 58
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
56
Pomalidomide Plus Dexamethasone
15
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
-7.08
20.435
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
-1.85
18.505
Not reported
Not reported
Not reported
DS, CFB to Week 61
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
51
Pomalidomide Plus Dexamethasone
16
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
-7.02
19.827
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
0.35
16.161
Not reported
Not reported
Not reported
DS, CFB to Week 64
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
49
Pomalidomide Plus Dexamethasone
14
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
-6.39
19.010
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
-5.95
16.803
Not reported
Not reported
Not reported
DS, CFB to Week 67
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
48
Pomalidomide Plus Dexamethasone
15
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
-11.04
16.693
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
-5.56
18.426
Not reported
Not reported
Not reported
DS, CFB to Week 70
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
48
Pomalidomide Plus Dexamethasone
13
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
-12.64
16.959
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
-8.12
15.976
Not reported
Not reported
Not reported
DS, CFB to Week 73
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
40
Pomalidomide Plus Dexamethasone
14
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
-9.36
15.274
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
-2.78
19.214
Not reported
Not reported
Not reported
DS, CFB to Week 76
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
42
Pomalidomide Plus Dexamethasone
15
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
-7.57
15.562
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
-5.19
13.684
Not reported
Not reported
Not reported
DS, CFB to Week 79
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
42
Pomalidomide Plus Dexamethasone
15
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
-8.39
15.938
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
-8.67
13.790
Not reported
Not reported
Not reported
DS, CFB to Week 82
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
43
Pomalidomide Plus Dexamethasone
15
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
-6.46
15.596
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
-10.00
15.459
Not reported
Not reported
Not reported
DS, CFB to Week 85
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
36
Pomalidomide Plus Dexamethasone
12
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
-7.69
14.917
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
-10.19
18.628
Not reported
Not reported
Not reported
DS, CFB to Week 88
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
36
Pomalidomide Plus Dexamethasone
12
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
-8.77
16.228
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
-11.57
17.957
Not reported
Not reported
Not reported
DS, CFB to Week 91
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
37
Pomalidomide Plus Dexamethasone
12
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
-8.26
17.888
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
-0.46
23.145
Not reported
Not reported
Not reported
DS, CFB to Week 94
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
36
Pomalidomide Plus Dexamethasone
11
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
-10.77
17.865
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
-4.04
20.502
Not reported
Not reported
Not reported
DS, CFB to Week 97
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
30
Pomalidomide Plus Dexamethasone
10
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
-8.30
14.783
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
-7.22
15.505
Not reported
Not reported
Not reported
DS, CFB to Week 100
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
35
Pomalidomide Plus Dexamethasone
10
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
-8.86
18.135
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
-3.89
22.688
Not reported
Not reported
Not reported
DS, CFB to Week 103
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
34
Pomalidomide Plus Dexamethasone
9
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
-8.79
17.518
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
-2.47
19.859
Not reported
Not reported
Not reported
DS, CFB to Week 106
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
33
Pomalidomide Plus Dexamethasone
6
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
-9.39
18.811
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
-0.93
17.362
Not reported
Not reported
Not reported
DS, CFB to Week 109
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
34
Pomalidomide Plus Dexamethasone
8
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
-7.81
14.082
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
-2.78
20.574
Not reported
Not reported
Not reported
DS, CFB to Week 112
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
29
Pomalidomide Plus Dexamethasone
7
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
-11.30
15.177
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
1.59
24.993
Not reported
Not reported
Not reported
DS, CFB to Week 115
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
30
Pomalidomide Plus Dexamethasone
8
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
-7.41
14.468
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
-2.08
15.974
Not reported
Not reported
Not reported
DS, CFB to Week 118
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
30
Pomalidomide Plus Dexamethasone
8
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
-6.67
16.272
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
0.00
21.207
Not reported
Not reported
Not reported
DS, CFB to Week 121
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
26
Pomalidomide Plus Dexamethasone
8
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
-4.91
25.256
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
-2.08
23.181
Not reported
Not reported
Not reported
DS, CFB to Week 124
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
25
Pomalidomide Plus Dexamethasone
6
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
-11.56
17.192
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
-6.48
20.005
Not reported
Not reported
Not reported
DS, CFB to Week 127
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
26
Pomalidomide Plus Dexamethasone
6
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
-7.91
18.337
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
-5.56
19.245
Not reported
Not reported
Not reported
DS, CFB to Week 130
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
25
Pomalidomide Plus Dexamethasone
5
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
-12.00
14.316
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
-1.11
23.040
Not reported
Not reported
Not reported
DS, CFB to Week 133
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
24
Pomalidomide Plus Dexamethasone
6
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
-11.34
15.497
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
-4.63
25.680
Not reported
Not reported
Not reported
DS, CFB to Week 136
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
21
Pomalidomide Plus Dexamethasone
5
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
-8.99
19.283
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
-7.78
20.638
Not reported
Not reported
Not reported
DS, CFB to Week 139
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
21
Pomalidomide Plus Dexamethasone
6
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
-10.05
14.339
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
-11.11
22.222
Not reported
Not reported
Not reported
DS, CFB to Week 142
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
22
Pomalidomide Plus Dexamethasone
4
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
-7.83
13.131
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
-5.56
27.962
Not reported
Not reported
Not reported
DS, CFB to Week 145
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
18
Pomalidomide Plus Dexamethasone
5
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
-7.72
16.185
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
-3.33
22.083
Not reported
Not reported
Not reported
DS, CFB to Week 148
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
19
Pomalidomide Plus Dexamethasone
4
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
-7.89
16.283
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
-5.56
27.962
Not reported
Not reported
Not reported
DS, CFB to Week 151
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
21
Pomalidomide Plus Dexamethasone
4
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
-10.32
15.643
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
-8.33
20.538
Not reported
Not reported
Not reported
DS, CFB to Week 154
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
18
Pomalidomide Plus Dexamethasone
4
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
-9.26
17.568
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
2.78
31.914
Not reported
Not reported
Not reported
DS, CFB to Week 157
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
17
Pomalidomide Plus Dexamethasone
3
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
-10.13
16.344
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
-5.56
36.430
Not reported
Not reported
Not reported
DS, CFB to Week 160
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
18
Pomalidomide Plus Dexamethasone
3
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
-5.56
20.076
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
5.56
52.997
Not reported
Not reported
Not reported
DS, CFB to Week 163
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
18
Pomalidomide Plus Dexamethasone
3
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
-9.26
19.339
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
-1.85
36.147
Not reported
Not reported
Not reported
DS, CFB to Week 166
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
15
Pomalidomide Plus Dexamethasone
3
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
-11.11
18.306
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
-3.70
39.021
Not reported
Not reported
Not reported
DS, CFB to Week 169
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
17
Pomalidomide Plus Dexamethasone
3
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
-7.84
17.684
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
-7.41
33.945
Not reported
Not reported
Not reported
DS, CFB to Week 172
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
13
Pomalidomide Plus Dexamethasone
3
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
-16.24
16.738
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
-9.26
31.590
Not reported
Not reported
Not reported
DS, CFB to Week 175
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
12
Pomalidomide Plus Dexamethasone
3
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
-13.43
17.157
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
-7.41
33.945
Not reported
Not reported
Not reported
DS, CFB to Week 178
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
14
Pomalidomide Plus Dexamethasone
3
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
-10.32
17.549
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
-16.67
24.216
Not reported
Not reported
Not reported
DS, CFB to Week 181
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
14
Pomalidomide Plus Dexamethasone
3
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
-9.92
15.281
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
-9.26
31.590
Not reported
Not reported
Not reported
DS, CFB to Week 184
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
11
Pomalidomide Plus Dexamethasone
3
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
-2.53
19.620
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
-5.56
36.430
Not reported
Not reported
Not reported
DS, CFB to Week 187
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
9
Pomalidomide Plus Dexamethasone
2
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
-2.47
16.224
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
-5.56
54.997
Not reported
Not reported
Not reported
DS, CFB to Week 190
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
10
Pomalidomide Plus Dexamethasone
3
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
-5.00
21.667
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
-3.70
39.021
Not reported
Not reported
Not reported
DS, CFB to Week 193
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
7
Pomalidomide Plus Dexamethasone
3
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
-3.17
7.069
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
-9.26
31.590
Not reported
Not reported
Not reported
DS, CFB to Week 196
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
9
Pomalidomide Plus Dexamethasone
3
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
-12.35
17.073
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
-13.70
26.674
Not reported
Not reported
Not reported
DS, CFB to Week 199
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
7
Pomalidomide Plus Dexamethasone
3
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
-2.38
14.649
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
-5.56
36.430
Not reported
Not reported
Not reported
DS, CFB to Week 202
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
9
Pomalidomide Plus Dexamethasone
3
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
-9.88
18.794
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
-7.41
33.945
Not reported
Not reported
Not reported
DS, CFB to Week 205
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
7
Pomalidomide Plus Dexamethasone
2
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
-11.11
23.130
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
13.89
19.642
Not reported
Not reported
Not reported
DS, CFB to Week 208
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
7
Pomalidomide Plus Dexamethasone
2
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
-11.90
21.855
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
8.33
11.785
Not reported
Not reported
Not reported
DS, CFB to Week 211
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
5
Pomalidomide Plus Dexamethasone
2
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
-11.11
23.895
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
13.89
19.642
Not reported
Not reported
Not reported
DS, CFB to Week 214
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
3
Pomalidomide Plus Dexamethasone
2
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
-14.81
30.598
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
13.89
19.642
Not reported
Not reported
Not reported
DS, CFB to Week 217
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
2
Pomalidomide Plus Dexamethasone
2
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
0.00
0.000
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
13.89
19.642
Not reported
Not reported
Not reported
DS, CFB to Week 220
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
2
Pomalidomide Plus Dexamethasone
2
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
-2.78
3.928
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
5.56
7.857
Not reported
Not reported
Not reported
DS, CFB to Week 223
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
4
Pomalidomide Plus Dexamethasone
2
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
-1.39
6.991
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
-2.78
3.928
Not reported
Not reported
Not reported
DS, CFB to Week 226
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
3
Pomalidomide Plus Dexamethasone
1
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
-5.56
9.623
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
16.67
NA
Not reported
Not reported
Standard Deviation is not evaluable for a single participant.
DS, CFB to Week 229
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
2
Pomalidomide Plus Dexamethasone
1
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
-8.33
11.785
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
16.67
NA
Not reported
Not reported
Standard Deviation is not evaluable for a single participant.
DS, CFB to Week 232
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
3
Pomalidomide Plus Dexamethasone
1
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
-1.85
8.486
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
22.22
NA
Not reported
Not reported
Standard Deviation is not evaluable for a single participant.
DS, CFB to Week 235
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
2
Pomalidomide Plus Dexamethasone
1
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
0.00
0.000
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
16.67
NA
Not reported
Not reported
Standard Deviation is not evaluable for a single participant.
DS, CFB to Week 238
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
0
Pomalidomide Plus Dexamethasone
1
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Pomalidomide Plus Dexamethasone
16.67
NA
Not reported
Not reported
Standard Deviation is not evaluable for a single participant.
DS, CFB to EOT (~242 weeks)
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
118
Pomalidomide Plus Dexamethasone
66
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
1.44
21.907
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
-1.23
18.763
Not reported
Not reported
Not reported
DS, CFB to LFU (~263 weeks)
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
55
Pomalidomide Plus Dexamethasone
15
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
-2.12
22.907
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
-15.93
23.370
Not reported
Not reported
Not reported
SET, CFB to Week 4
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
33
Pomalidomide Plus Dexamethasone
14
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
-2.18
7.659
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
3.92
11.722
Not reported
Not reported
Not reported
SET, CFB to Week 7
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
30
Pomalidomide Plus Dexamethasone
16
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
0.69
8.787
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
-1.90
8.875
Not reported
Not reported
Not reported
SET, CFB to Week 10
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
28
Pomalidomide Plus Dexamethasone
12
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
0.09
11.303
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
-0.90
11.107
Not reported
Not reported
Not reported
SET, CFB to Week 13
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
25
Pomalidomide Plus Dexamethasone
13
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
-1.33
9.146
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
0.19
14.300
Not reported
Not reported
Not reported
SET, CFB to Week 16
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
24
Pomalidomide Plus Dexamethasone
15
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
-1.81
9.856
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
-1.98
12.199
Not reported
Not reported
Not reported
SET, CFB to Week 19
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
22
Pomalidomide Plus Dexamethasone
12
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
-0.22
8.596
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
-2.16
14.177
Not reported
Not reported
Not reported
SET, CFB to Week 22
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
23
Pomalidomide Plus Dexamethasone
12
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
-1.16
8.625
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
-2.58
12.207
Not reported
Not reported
Not reported
SET, CFB to Week 25
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
24
Pomalidomide Plus Dexamethasone
6
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
-3.23
9.781
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
4.65
11.792
Not reported
Not reported
Not reported
SET, CFB to Week 28
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
21
Pomalidomide Plus Dexamethasone
8
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
-2.49
6.870
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
-3.10
8.196
Not reported
Not reported
Not reported
SET, CFB to Week 31
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
21
Pomalidomide Plus Dexamethasone
8
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
-2.77
9.936
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
-4.77
13.877
Not reported
Not reported
Not reported
SET, CFB to Week 34
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
19
Pomalidomide Plus Dexamethasone
7
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
-0.76
7.892
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
-6.24
10.216
Not reported
Not reported
Not reported
SET, CFB to Week 37
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
18
Pomalidomide Plus Dexamethasone
8
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
-2.08
8.579
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
2.31
9.645
Not reported
Not reported
Not reported
SET, CFB to Week 40
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
18
Pomalidomide Plus Dexamethasone
8
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
-3.09
11.054
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
-1.81
7.305
Not reported
Not reported
Not reported
SET, CFB to Week 43
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
18
Pomalidomide Plus Dexamethasone
7
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
-2.37
11.113
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
-1.64
10.541
Not reported
Not reported
Not reported
SET, CFB to Week 46
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
16
Pomalidomide Plus Dexamethasone
5
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
-3.06
8.828
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
3.48
3.606
Not reported
Not reported
Not reported
SET, CFB to Week 49
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
17
Pomalidomide Plus Dexamethasone
6
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
-2.18
6.875
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
1.17
7.617
Not reported
Not reported
Not reported
SET, CFB to Week 52
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
14
Pomalidomide Plus Dexamethasone
7
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
-4.10
6.707
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
-4.50
7.433
Not reported
Not reported
Not reported
SET, CFB to Week 55
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
13
Pomalidomide Plus Dexamethasone
7
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
-3.79
8.101
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
-0.11
8.475
Not reported
Not reported
Not reported
SET, CFB to Week 58
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
14
Pomalidomide Plus Dexamethasone
7
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
0.26
10.728
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
-3.07
6.200
Not reported
Not reported
Not reported
SET, CFB to Week 61
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
14
Pomalidomide Plus Dexamethasone
7
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
-1.01
9.369
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
-0.21
8.462
Not reported
Not reported
Not reported
SET, CFB to Week 64
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
13
Pomalidomide Plus Dexamethasone
5
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
-1.08
7.905
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
-0.30
6.150
Not reported
Not reported
Not reported
SET, CFB to Week 67
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
14
Pomalidomide Plus Dexamethasone
5
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
-2.57
7.500
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
-1.70
6.228
Not reported
Not reported
Not reported
SET, CFB to Week 70
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
13
Pomalidomide Plus Dexamethasone
5
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
-1.40
8.276
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
-3.63
5.168
Not reported
Not reported
Not reported
SET, CFB to Week 73
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
10
Pomalidomide Plus Dexamethasone
5
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
0.54
10.793
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
-0.30
5.402
Not reported
Not reported
Not reported
SET, CFB to Week 76
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
12
Pomalidomide Plus Dexamethasone
5
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
-0.06
7.798
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
-1.04
6.189
Not reported
Not reported
Not reported
SET, CFB to Week 79
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
11
Pomalidomide Plus Dexamethasone
5
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
-3.80
8.576
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
-2.37
4.897
Not reported
Not reported
Not reported
SET, CFB to Week 82
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
11
Pomalidomide Plus Dexamethasone
5
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
-2.69
7.496
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
-5.04
5.320
Not reported
Not reported
Not reported
SET, CFB to Week 85
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
8
Pomalidomide Plus Dexamethasone
3
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
1.44
9.980
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
-1.36
4.777
Not reported
Not reported
Not reported
SET, CFB to Week 88
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
11
Pomalidomide Plus Dexamethasone
3
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
1.16
8.321
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
-1.36
8.049
Not reported
Not reported
Not reported
SET, CFB to Week 91
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
8
Pomalidomide Plus Dexamethasone
3
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
-0.74
8.654
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
6.42
3.361
Not reported
Not reported
Not reported
SET, CFB to Week 94
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
10
Pomalidomide Plus Dexamethasone
3
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
-2.07
8.985
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
-0.25
2.971
Not reported
Not reported
Not reported
SET, CFB to Week 97
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
8
Pomalidomide Plus Dexamethasone
3
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
-2.64
8.772
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
-0.25
8.545
Not reported
Not reported
Not reported
SET, CFB to Week 100
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
7
Pomalidomide Plus Dexamethasone
3
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
-3.39
10.142
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
-1.36
8.049
Not reported
Not reported
Not reported
SET, CFB to Week 103
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
8
Pomalidomide Plus Dexamethasone
3
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
-0.93
9.147
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
-1.36
1.750
Not reported
Not reported
Not reported
SET, CFB to Week 106
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
6
Pomalidomide Plus Dexamethasone
1
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
-1.85
5.781
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
-0.74
NA
Not reported
Not reported
Standard Deviation is not evaluable for a single participant.
SET, CFB to Week 109
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
8
Pomalidomide Plus Dexamethasone
3
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
-0.93
8.508
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
-5.80
6.833
Not reported
Not reported
Not reported
SET, CFB to Week 112
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
6
Pomalidomide Plus Dexamethasone
2
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
-2.84
7.138
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
-5.37
15.975
Not reported
Not reported
Not reported
SET, CFB to Week 115
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
7
Pomalidomide Plus Dexamethasone
3
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
-2.65
9.475
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
-3.46
8.837
Not reported
Not reported
Not reported
SET, CFB to Week 118
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
7
Pomalidomide Plus Dexamethasone
3
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
1.43
10.720
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
6.54
5.242
Not reported
Not reported
Not reported
SET, CFB to Week 121
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
7
Pomalidomide Plus Dexamethasone
3
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
1.11
10.005
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
0.12
12.408
Not reported
Not reported
Not reported
SET, CFB to Week 124
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
5
Pomalidomide Plus Dexamethasone
2
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
4.67
14.519
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
-2.04
20.689
Not reported
Not reported
Not reported
SET, CFB to Week 127
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
6
Pomalidomide Plus Dexamethasone
2
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
2.65
8.816
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
6.67
1.048
Not reported
Not reported
Not reported
SET, CFB to Week 130
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
6
Pomalidomide Plus Dexamethasone
1
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
2.35
7.343
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
-0.74
NA
Not reported
Not reported
Standard Deviation is not evaluable for a single participant.
SET, CFB to Week 133
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
5
Pomalidomide Plus Dexamethasone
2
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
0.59
8.201
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
2.78
3.928
Not reported
Not reported
Not reported
SET, CFB to Week 136
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
3
Pomalidomide Plus Dexamethasone
1
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
5.90
3.885
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
11.11
NA
Not reported
Not reported
Standard Deviation is not evaluable for a single participant.
SET, CFB to Week 139
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
4
Pomalidomide Plus Dexamethasone
2
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
9.63
10.102
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
4.63
3.928
Not reported
Not reported
Not reported
SET, CFB to Week 142
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
4
Pomalidomide Plus Dexamethasone
0
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
7.31
8.003
Not reported
Not reported
Not reported
SET, CFB to Week 145
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
3
Pomalidomide Plus Dexamethasone
1
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
9.88
4.277
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
3.70
NA
Not reported
Not reported
Standard Deviation is not evaluable for a single participant.
SET, CFB to Week 148
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
3
Pomalidomide Plus Dexamethasone
1
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
2.96
8.543
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
3.70
NA
Not reported
Not reported
Standard Deviation is not evaluable for a single participant.
SET, CFB to Week 151
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
3
Pomalidomide Plus Dexamethasone
1
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
7.41
3.704
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
3.70
NA
Not reported
Not reported
Standard Deviation is not evaluable for a single participant.
SET, CFB to Week 154
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
2
Pomalidomide Plus Dexamethasone
1
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
9.26
2.619
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
3.70
NA
Not reported
Not reported
Standard Deviation is not evaluable for a single participant.
SET, CFB to Week 157
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
4
Pomalidomide Plus Dexamethasone
0
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
6.85
6.985
Not reported
Not reported
Not reported
SET, CFB to Week 160
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
3
Pomalidomide Plus Dexamethasone
0
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
6.67
4.857
Not reported
Not reported
Not reported
SET, CFB to Week 163
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
2
Pomalidomide Plus Dexamethasone
0
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
6.30
6.809
Not reported
Not reported
Not reported
SET, CFB to Week 166
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
2
Pomalidomide Plus Dexamethasone
0
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
5.56
2.619
Not reported
Not reported
Not reported
SET, CFB to Week 169
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
2
Pomalidomide Plus Dexamethasone
0
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
7.41
5.238
Not reported
Not reported
Not reported
SET, CFB to Week 172
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
1
Pomalidomide Plus Dexamethasone
0
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
3.70
NA
Not reported
Not reported
Standard Deviation is not evaluable for a single participant.
SET, CFB to Week 175
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
1
Pomalidomide Plus Dexamethasone
0
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
11.11
NA
Not reported
Not reported
Standard Deviation is not evaluable for a single participant.
SET, CFB to Week 178
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
1
Pomalidomide Plus Dexamethasone
0
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
0.00
NA
Not reported
Not reported
Standard Deviation is not evaluable for a single participant.
SET, CFB to Week 181
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
1
Pomalidomide Plus Dexamethasone
0
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
0.00
NA
Not reported
Not reported
Standard Deviation is not evaluable for a single participant.
SET, CFB to EOT (~242 weeks)
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
23
Pomalidomide Plus Dexamethasone
13
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
1.73
13.594
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
-1.34
15.436
Not reported
Not reported
Not reported
SET, CFB to LFU (~263 weeks)
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
15
Pomalidomide Plus Dexamethasone
3
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
4.62
12.905
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
14.69
21.787
Not reported
Not reported
Not reported
FP, CFB to Week 4
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
33
Pomalidomide Plus Dexamethasone
14
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
-3.37
18.939
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
3.97
14.194
Not reported
Not reported
Not reported
FP, CFB to Week 7
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
30
Pomalidomide Plus Dexamethasone
16
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
1.48
19.947
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
7.64
9.702
Not reported
Not reported
Not reported
FP, CFB to Week 10
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
27
Pomalidomide Plus Dexamethasone
12
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
1.65
19.172
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
12.96
18.247
Not reported
Not reported
Not reported
FP, CFB to Week 13
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
25
Pomalidomide Plus Dexamethasone
13
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
1.33
20.367
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
15.38
18.447
Not reported
Not reported
Not reported
FP, CFB to Week 16
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
24
Pomalidomide Plus Dexamethasone
15
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
0.93
17.312
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
15.56
23.682
Not reported
Not reported
Not reported
FP, CFB to Week 19
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
22
Pomalidomide Plus Dexamethasone
12
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
8.08
17.207
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
16.67
22.473
Not reported
Not reported
Not reported
FP, CFB to Week 22
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
23
Pomalidomide Plus Dexamethasone
12
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
6.28
12.900
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
9.26
24.995
Not reported
Not reported
Not reported
FP, CFB to Week 25
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
24
Pomalidomide Plus Dexamethasone
6
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
6.48
19.908
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
5.56
11.653
Not reported
Not reported
Not reported
FP, CFB to Week 28
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
21
Pomalidomide Plus Dexamethasone
8
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
9.52
17.315
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
11.11
14.548
Not reported
Not reported
Not reported
FP, CFB to Week 31
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
21
Pomalidomide Plus Dexamethasone
8
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
8.47
24.064
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
12.50
20.945
Not reported
Not reported
Not reported
FP, CFB to Week 34
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
19
Pomalidomide Plus Dexamethasone
7
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
9.36
17.476
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
11.11
20.286
Not reported
Not reported
Not reported
FP, CFB to Week 37
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
18
Pomalidomide Plus Dexamethasone
8
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
12.35
20.835
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
6.94
23.710
Not reported
Not reported
Not reported
FP, CFB to Week 40
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
18
Pomalidomide Plus Dexamethasone
8
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
9.88
23.766
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
4.17
22.954
Not reported
Not reported
Not reported
FP, CFB to Week 43
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
18
Pomalidomide Plus Dexamethasone
7
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
14.20
24.641
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
6.35
27.108
Not reported
Not reported
Not reported
FP, CFB to Week 46
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
16
Pomalidomide Plus Dexamethasone
5
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
6.94
20.638
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
-4.44
30.021
Not reported
Not reported
Not reported
FP, CFB to Week 49
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
17
Pomalidomide Plus Dexamethasone
6
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
13.07
24.291
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
7.41
19.458
Not reported
Not reported
Not reported
FP, CFB to Week 52
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
14
Pomalidomide Plus Dexamethasone
7
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
6.35
18.343
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
14.29
19.994
Not reported
Not reported
Not reported
FP, CFB to Week 55
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
13
Pomalidomide Plus Dexamethasone
7
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
8.55
17.066
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
4.76
21.138
Not reported
Not reported
Not reported
FP, CFB to Week 58
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
14
Pomalidomide Plus Dexamethasone
7
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
-3.17
19.698
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
7.94
16.623
Not reported
Not reported
Not reported
FP, CFB to Week 61
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
14
Pomalidomide Plus Dexamethasone
7
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
2.38
20.056
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
12.70
23.508
Not reported
Not reported
Not reported
FP, CFB to Week 64
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
13
Pomalidomide Plus Dexamethasone
5
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
1.71
18.618
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
13.33
24.088
Not reported
Not reported
Not reported
FP, CFB to Week 67
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
14
Pomalidomide Plus Dexamethasone
5
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
3.97
16.076
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
15.56
23.040
Not reported
Not reported
Not reported
FP, CFB to Week 70
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
13
Pomalidomide Plus Dexamethasone
5
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
5.13
15.460
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
4.44
16.851
Not reported
Not reported
Not reported
FP, CFB to Week 73
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
10
Pomalidomide Plus Dexamethasone
5
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
-2.22
20.820
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
11.11
19.245
Not reported
Not reported
Not reported
FP, CFB to Week 76
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
12
Pomalidomide Plus Dexamethasone
5
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
4.63
19.221
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
11.11
26.058
Not reported
Not reported
Not reported
FP, CFB to Week 79
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
11
Pomalidomide Plus Dexamethasone
5
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
1.01
16.817
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
11.11
26.058
Not reported
Not reported
Not reported
FP, CFB to Week 82
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
11
Pomalidomide Plus Dexamethasone
5
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
3.03
19.933
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
13.33
25.337
Not reported
Not reported
Not reported
FP, CFB to Week 85
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
8
Pomalidomide Plus Dexamethasone
3
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
-1.39
28.753
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
0.00
19.245
Not reported
Not reported
Not reported
FP, CFB to Week 88
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
11
Pomalidomide Plus Dexamethasone
3
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
-2.02
24.251
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
3.70
12.830
Not reported
Not reported
Not reported
FP, CFB to Week 91
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
8
Pomalidomide Plus Dexamethasone
3
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
1.39
25.502
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
0.00
11.111
Not reported
Not reported
Not reported
FP, CFB to Week 94
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
10
Pomalidomide Plus Dexamethasone
3
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
4.44
22.345
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
3.70
12.830
Not reported
Not reported
Not reported
FP, CFB to Week 97
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
8
Pomalidomide Plus Dexamethasone
3
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
12.50
18.245
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
-11.11
11.111
Not reported
Not reported
Not reported
FP, CFB to Week 100
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
7
Pomalidomide Plus Dexamethasone
3
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
4.76
17.982
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
-7.41
16.973
Not reported
Not reported
Not reported
FP, CFB to Week 103
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
8
Pomalidomide Plus Dexamethasone
3
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
1.39
22.567
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
-14.81
6.415
Not reported
Not reported
Not reported
FP, CFB to Week 106
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
6
Pomalidomide Plus Dexamethasone
1
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
3.70
13.456
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
0.00
NA
Not reported
Not reported
Standard Deviation is not evaluable for a single participant.
FP, CFB to Week 109
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
8
Pomalidomide Plus Dexamethasone
3
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
2.78
14.242
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
-18.52
6.415
Not reported
Not reported
Not reported
FP, CFB to Week 112
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
6
Pomalidomide Plus Dexamethasone
2
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
5.56
20.787
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
-11.11
15.713
Not reported
Not reported
Not reported
FP, CFB to Week 115
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
7
Pomalidomide Plus Dexamethasone
3
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
6.35
17.982
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
-18.52
6.415
Not reported
Not reported
Not reported
FP, CFB to Week 118
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
7
Pomalidomide Plus Dexamethasone
3
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
-3.17
12.363
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
-18.52
6.415
Not reported
Not reported
Not reported
FP, CFB to Week 121
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
7
Pomalidomide Plus Dexamethasone
3
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
6.35
16.798
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
-18.52
6.415
Not reported
Not reported
Not reported
FP, CFB to Week 124
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
5
Pomalidomide Plus Dexamethasone
2
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
-11.11
26.058
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
-16.67
7.857
Not reported
Not reported
Not reported
FP, CFB to Week 127
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
6
Pomalidomide Plus Dexamethasone
2
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
1.85
12.989
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
-16.67
7.857
Not reported
Not reported
Not reported
FP, CFB to Week 130
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
6
Pomalidomide Plus Dexamethasone
1
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
1.85
16.355
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
0.00
NA
Not reported
Not reported
Standard Deviation is not evaluable for a single participant.
FP, CFB to Week 133
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
5
Pomalidomide Plus Dexamethasone
2
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
0.00
15.713
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
-22.22
0.000
Not reported
Not reported
Not reported
FP, CFB to Week 136
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
3
Pomalidomide Plus Dexamethasone
1
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
0.00
29.397
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
-22.22
NA
Not reported
Not reported
Standard Deviation is not evaluable for a single participant.
FP, CFB to Week 139
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
4
Pomalidomide Plus Dexamethasone
2
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
5.56
19.245
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
-22.22
0.000
Not reported
Not reported
Not reported
FP, CFB to Week 142
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
4
Pomalidomide Plus Dexamethasone
0
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
5.56
21.276
Not reported
Not reported
Not reported
FP, CFB to Week 145
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
3
Pomalidomide Plus Dexamethasone
1
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
7.41
25.660
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
-22.22
NA
Not reported
Not reported
Standard Deviation is not evaluable for a single participant.
FP, CFB to Week 148
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
3
Pomalidomide Plus Dexamethasone
1
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
7.41
16.973
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
-22.22
NA
Not reported
Not reported
Standard Deviation is not evaluable for a single participant.
FP, CFB to Week 151
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
3
Pomalidomide Plus Dexamethasone
1
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
11.11
19.245
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
-22.22
NA
Not reported
Not reported
Standard Deviation is not evaluable for a single participant.
FP, CFB to Week 154
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
2
Pomalidomide Plus Dexamethasone
1
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
11.11
31.427
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
-22.22
Not reported
Not reported
Not reported
Not reported
FP, CFB to Week 157
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
4
Pomalidomide Plus Dexamethasone
0
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
13.89
16.667
Not reported
Not reported
Not reported
FP, CFB to Week 160
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
3
Pomalidomide Plus Dexamethasone
0
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
7.41
16.973
Not reported
Not reported
Not reported
FP, CFB to Week 163
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
2
Pomalidomide Plus Dexamethasone
0
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
0.00
15.713
Not reported
Not reported
Not reported
FP, CFB to Week 166
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
2
Pomalidomide Plus Dexamethasone
0
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
16.67
7.857
Not reported
Not reported
Not reported
FP, CFB to Week 169
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
2
Pomalidomide Plus Dexamethasone
0
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
11.11
0.000
Not reported
Not reported
Not reported
FP, CFB to Week 172
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
1
Pomalidomide Plus Dexamethasone
0
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
-11.11
NA
Not reported
Not reported
Standard Deviation is not evaluable for a single participant.
FP, CFB to Week 175
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
1
Pomalidomide Plus Dexamethasone
0
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
-11.11
NA
Not reported
Not reported
Standard Deviation is not evaluable for a single participant.
FP, CFB to Week 178
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
1
Pomalidomide Plus Dexamethasone
0
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
11.11
NA
Not reported
Not reported
Standard Deviation is not evaluable for a single participant.
FP, CFB to Week 181
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
1
Pomalidomide Plus Dexamethasone
0
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
22.22
NA
Not reported
Not reported
Standard Deviation is not evaluable for a single participant.
FP, CFB to EOT (~242 weeks)
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
23
Pomalidomide Plus Dexamethasone
13
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
-14.01
32.862
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
-5.13
29.262
Not reported
Not reported
Not reported
FP, CFB to LFU (~263 weeks)
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
15
Pomalidomide Plus Dexamethasone
3
Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
-6.67
20.053
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
-25.93
27.962
Not reported
Not reported
Not reported
Complete source fields
classes
categories
measurements
group Id
OG000
spread
21.663
value
7.07
group Id
OG001
spread
19.298
value
7.14
denoms
counts
group Id
OG000
value
33
group Id
OG001
value
14
units
Participants
title
BI, CFB to Week 4
categories
measurements
group Id
OG000
spread
27.310
value
-4.44
group Id
OG001
spread
19.124
value
2.08
denoms
counts
group Id
OG000
value
30
group Id
OG001
value
16
units
Participants
title
BI, CFB to Week 7
categories
measurements
group Id
OG000
spread
21.645
value
-1.23
group Id
OG001
spread
19.245
value
5.56
denoms
counts
group Id
OG000
value
27
group Id
OG001
value
12
units
Participants
title
BI, CFB to Week 10
categories
measurements
group Id
OG000
spread
20.367
value
1.33
group Id
OG001
spread
22.958
value
5.13
denoms
counts
group Id
OG000
value
25
group Id
OG001
value
13
units
Participants
title
BI, CFB to Week 13
categories
measurements
group Id
OG000
spread
26.580
value
-4.17
group Id
OG001
spread
24.774
value
-4.44
denoms
counts
group Id
OG000
value
24
group Id
OG001
value
15
units
Participants
title
BI, CFB to Week 16
categories
measurements
group Id
OG000
spread
20.339
value
-3.03
group Id
OG001
spread
21.711
value
11.11
denoms
counts
group Id
OG000
value
22
group Id
OG001
value
12
units
Participants
title
BI, CFB to Week 19
categories
measurements
group Id
OG000
spread
21.678
value
5.80
group Id
OG001
spread
14.213
value
0.00
denoms
counts
group Id
OG000
value
23
group Id
OG001
value
12
units
Participants
title
BI, CFB to Week 22
categories
measurements
group Id
OG000
spread
23.008
value
-1.39
group Id
OG001
spread
21.082
value
0.00
denoms
counts
group Id
OG000
value
24
group Id
OG001
value
6
units
Participants
title
BI, CFB to Week 25
categories
measurements
group Id
OG000
spread
21.822
value
4.76
group Id
OG001
spread
25.198
value
0.00
denoms
counts
group Id
OG000
value
21
group Id
OG001
value
8
units
Participants
title
BI, CFB to Week 28
categories
measurements
group Id
OG000
spread
24.234
value
4.76
group Id
OG001
spread
23.570
value
8.33
denoms
counts
group Id
OG000
value
21
group Id
OG001
value
8
units
Participants
title
BI, CFB to Week 31
categories
measurements
group Id
OG000
spread
25.491
value
5.26
group Id
OG001
spread
23.002
value
4.76
denoms
counts
group Id
OG000
value
19
group Id
OG001
value
7
units
Participants
title
BI, CFB to Week 34
categories
measurements
group Id
OG000
spread
28.006
value
0.00
group Id
OG001
spread
21.362
value
-4.17
denoms
counts
group Id
OG000
value
18
group Id
OG001
value
8
units
Participants
title
BI, CFB to Week 37
denoms
counts
group Id
OG000
value
218
group Id
OG001
value
107
units
Participants
description
The EORTC QLQ-MY20 is a supplement to the QLQ-C30 instrument used in participants with multiple myeloma. The module comprised of 20 questions that addressed four myeloma-specific HRQoL domains: disease symptoms (DS), side effects of treatment (SET), future perspective (FP) and body image (BI). Responses are 1 to 4. Scores were averaged and scales were transformed to 0 to 100 scale. A high score for disease symptoms and side effects of treatment represented a high level of symptomatology or problems, whereas a high score for future perspective and body image represented better outcomes. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits.
dispersion Type
Standard Deviation
groups
description
Participants with relapsed/refractory multiple myeloma (RRMM) received 30 minutes intravenous infusion of 2.5 milligram/kilogram (mg/kg) belantamab mafodotin on day 1 of each 21-day cycle
id
OG000
title
Belantamab Mafodotin
description
Participants with RRMM received 4 mg pomalidomide capsule daily on Days 1 to 21 of each 28-day cycle, along with 40 mg or at lower 20 mg (for participants \>75 years of age) dose of dexamethasone tablet once weekly (Days 1, 8, 15 and 22)
id
OG001
title
Pomalidomide Plus Dexamethasone
param Type
MEAN
population Description
ITT Population. Only those participants with data available in specified timepoints have been presented. Rows and Arms/Groups with 0 participants analyzed represent time points at which no participant data was available from within the respective Arms/Groups.
reporting Status
POSTED
time Frame
Baseline (Day 1), every three weeks(Q3W) starting from week 4 until week 238, End of Treatment (~242 weeks) and Follow up (~263 weeks)
title
Change From Baseline (CFB) in EORTC QLQ 20-item Multiple Myeloma Module (MY20) Score
Triangle